Abstract CT256: A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis

Abstract Background: Advanced angiosarcoma is a rare and aggressive sarcoma which is most often fatal, with a median progression free survival of 4-6 months on standard therapy. Therefore, innovative treatment regimens are urgently needed. Methods: Endpoints: Primary: Progression Free Survival; Secondary: Best overall response; Overall Survival; Incidence and severity of adverse events. Eligibility: 18 years, confirmed diagnosis of advanced angiosarcoma, acceptable hematologic and organ function. Treatment Schedule: Gemcitabine (600 mg/m2; max: 1000 mg), doxorubicin (18 mg/m2; max: 32 mg), docetaxel (25 mg/m2; max: 42 mg) on Days 1 and 8, and nivolumab (240 mg) on Day 1 of a 3-week cycle. Results: Median prior regimens = 1 (range 0-9). Efficacy: 7 of 9 patients who completed at least 2 treatment cycles and follow-up imaging (modified ITT population) were evaluated for: Median PFS: 9. 4 months (95% CI: 8. 224 to 9. 441; 7 events, 0 censored) ; Best response: Confirmed 1 CR, 3 PR, 3 SD; ORR = 57%; DCR = 100%. Nine patients who received at least one dose of each chemotherapy agent (ITT population) were evaluated for: Median OS: 28. 4 months (95% CI: 0. 724 to 31. 217; 5 events, 4 censored). Safety: 8 of 9 (89%) patients experienced a ≥ Grade 3 TRAE: leukopenia (n=6), thrombocytopenia (n=4), neutropenia (n=5), anemia (n=2), lymphopenia (n=2), fatigue (n=1), dec. LVEF (n=1), periorbital edema (n=1), limb edema (n=1) and worsening hypothyroidism (n=1). There were no Grade 5 nor unexpected adverse events. Conclusion: This metronomic chemo/immunotherapy regimen may be a synergistic and effective therapy for advanced angiosarcoma with manageable toxicity. Citation Format: Samantha Jeffrey, Piya Mann, Oliver Davidorf, Anmol Dia Agarwal, Sarah Lande, Mihir Chawla, Neal Chawla, Ania Moradkhani, Ted Kim, Victoria Chua-Alcala, Sant Chawla, Erlinda Gordon. A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr CT256.